You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

109 search results for: chronic inflammation

expert video

Neuroimmune Axis Dysregulation and Type 2 Inflammation: Shared Roles in AD, PN, and CSU

9 min

Dermatology

Exploration of the shared type 2 inflammation and neuroimmune axis dysfunction in AD, PN, and CSU leading to itch.

CRSwNP: A <b>Chronic</b> Type 2 Inflammatory Disease

expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

2 min

Rhinology

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.

expert video

Shared and Unique Characteristics of AD, PN, and CSU

17 min

Dermatology

Review the roles of type 2 inflammation in the skin manifestations and itch in these chronic skin conditions.

expert video

Type 2 Inflammation Contributes to the Signs and Symptoms of AD and PN

6 min

Dermatology

The impact of type 2 inflammation, neuroimmune axis dysfunction, and skin tissue on the signs and symptoms of atopic dermatitis and prurigo nodularis.

expert video

PN and AD: Distinct Diseases with Underlying Type 2 Inflammation

1 min

Dermatology

Prurigo nodularis (PN) and atopic dermatitis (AD): Distinct diseases with underlying type 2 inflammation – highlights from the ADVENT symposium at AAD 2023.

Cutaneous Manifestations in AD & PN: Role of Type 2 <b>Inflammation</b> video

expert video

Cutaneous Manifestations in AD & PN: Role of Type 2 Inflammation video

24 min

Dermatology

Type 2 inflammation in the distinct cutaneous manifestations of atopic dermatitis and prurigo nodularis – a clip from the ADVENT symposium at AAD 2023.

expert video

A brief overview of the pathophysiology of PN

5 min

Dermatology

Dr. Chovatiya explains that PN is primarily a chronic itch disease with a complex pathophysiology involving neuronal changes, type 2 inflammation, and fibrotic skin processes, affecting patients' overall well-being.

expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

5 min

Dermatology

Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.

Fibrosis and Type 2 <b>Inflammation</b> in PN

expert video

Fibrosis and Type 2 Inflammation in PN

2 min

Dermatology

The pathophysiology of fibrosis, a key component of skin manifestations in prurigo nodularis – Highlight from the ADVENT symposium at AAD 2023

CRSwNP, Type 2 <b>Inflammation</b>, and Mechanisms of Action of Biologics

expert video

CRSwNP, Type 2 Inflammation, and Mechanisms of Action of Biologics

9 min

Rhinology

Prof. Philippe Gevaert describes the immune responses involved in nasal polyposis, and the prevalence of type 2 inflammation.

expert video

Multidisciplinary Partnership for Type 2 Inflammatory Diseases

18 min

Type 2 Inflammation

Drs. Thomas Casale, Mario Castro and Profs. Peter Hellings, Ian Pavord, Ulrike von Arnim, and Stephan Weidinger discuss multidisciplinary care

UCARE 2023: Targeting Type 2 <b>Inflammation</b> in CSU – Clinical and Mechanistic Implications

expert video

UCARE 2023: Targeting Type 2 Inflammation in CSU – Clinical and Mechanistic Implications

34 min

Dermatology

Exploring the role of type 2 inflammation and the neuroimmune axis in CSU, and how emerging therapeutics are targeting key molecules in these pathways.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region